NuVasive files IDE for Cerpass cervical Total Disc Replacement product

San Diego 06 July 2005NuVasive Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, has filed for an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA) to investigate the safety and efficacy of its Cerpass cervical Total Disc Replacement (TDR) product on June 30, 2005 as planned. Approval of the IDE from the FDA would allow the company to initiate a pivotal human clinical study of the device in the United States.


TDR replaces a damaged or degenerative diseased spinal disc and allows for flexibility in that space by retaining the normal biomechanics of the spine and preserving natural range of motion versus the traditional fusion procedures which replace the disc with implants that bridge the space and facilitate new bone growth to eliminate motion.

NuVasive's Cerpass cervical TDR product incorporates a ceramic-on-ceramic design that the company believes increases durability and eliminates the potential problems of wear debris from other bearing surfaces such as polyethylene. In pre-clinical testing, the Cerpass compared favourably to other artificial spinal discs currently in FDA clinical studies. Cerpass is also designed to ensure proper placement because of its "self-centering" feature. Cerpass is designed for implantation through an anterior approach to the cervical region of the spine, the front of the neck.

Alexis V. Lukianov, Chairman and Chief Executive Officer, stated: "The IDE filing for United States clinical trials of our Cerpass cervical TDR product represents a major milestone in NuVasive's artificial disc development efforts for motion preservation of the neck vertebrae. We believe the ceramic-on-ceramic design will achieve superior long-term wear characteristics compared to that of other bearing surfaces. Our initial TDR focus continues to be on the cervical region of the spine. We believe it offers a more substantial market opportunity and will experience a broader, more rapid adoption by spine surgeons particularly when coupled with our "self-centering" feature to simplify implantation. We plan to discuss the details of the FDA study for our Cerpass following IDE approval."

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The company's product portfolio is focused on applications in the over $2 billion United States spine fusion market. The company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as classic fusion implants.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision, a proprietary software-driven nerve avoidance system; MaXcess, a unique split-blade design retraction system; and specialized implants, like SpheRx and CoRoent, that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility.

NuVasive's classic fusion portfolio is comprised predominantly of proprietary saline packaged bone allografts and internal fixation products. NuVasive also has a robust R&D pipeline emphasizing both MAS and motion preservation products such as Total Disc Replacement (TDR). More company news is available in the VMW June 2005 article NuVasive launches SpheRx DBR minimally disruptive fixation system.

Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]